


Budget Impact Analysis of STRIDE (Tremelimumab + Durvalumab) versus Atezolizumab + Bevacizumab for Unresectable Hepatocellular Carcinoma: Qatari Payer and Societal Perspectives

Anas Hamad^{1,2*}, Kakil Rasul³, Alaaeldin Shablak³, Mariam Mohammed El-Attar⁴, Gihan Hamdy Elsis^{4,5}

¹ Pharmacy Department, National Center for Cancer Care & Research, Hamad Medical Corporation, Doha, Qatar
² College of Pharmacy, QU Health Sector, Qatar University, Doha, Qatar
³ Oncology Department, National Center for Cancer Care & Research, Hamad Medical Corporation, Doha, Qatar

⁴ HEOR Department, HTA Office, Middle East and North Africa, Cairo, Egypt
⁵ Economics Department, American University in Cairo, Cairo, Egypt



BACKGROUND

Hepatocellular carcinoma (HCC) presents a major global public health issue:



Drawback of the current therapy:

While current first-line systemic combination therapy of Atezolizumab/Bevacizumab shows efficacy for patients with advanced or unresectable HCC, a proportion of patients become ineligible due to bleeding risk, highlighting the unmet clinical need for safer and equally effective alternatives



OBJECTIVE

The study evaluated the budget impact of introducing STRIDE regimen as an alternative therapy for the treatment of unresectable HCC from the Qatari healthcare payer and societal perspectives



METHODOS

Model approach

Using a static model, STRIDE was evaluated as a new first-line treatment option, partially replacing Atezolizumab/Bevacizumab and fully replacing Sorafenib

Cost source

Costs were retrieved from local cost databases and are presented in Qatari Riyals (QAR)

Time horizon

The analysis was conducted over three years

Clinical parameters


Clinical inputs, including treatment protocols and adverse event rates, were primarily sourced from the HIMALAYA and IMbrave150 clinical trials

Cost parameters

Direct medical costs (drug acquisition, adverse event management, and administration) and indirect costs

Sensitivity analysis

A deterministic sensitivity analysis assessed model robustness



RESULTS




Figure (2): Drug Costs




Figure (3): Total Non-Drug Costs Over The Time Horizon




Figure (4): Total Costs From Qatari Societal Perspective




Figure (5): Total Costs From Qatari Healthcare Payer Perspective

Deterministic sensitivity analysis indicated Atezolizumab/Bevacizumab share as the most impactful parameter



CONCLUSION

The study highlighted STRIDE as a valuable, **cost-saving** alternative for unresectable HCC patients in Qatar, particularly those ineligible for locoregional therapy or bevacizumab-containing regimens, thereby supporting its integration into clinical practice to address critical unmet treatment needs and manage healthcare costs effectively

* Address any correspondence to:

Dr. Anas Hamad, Email: ahamad6@hamad.qa

Acknowledgement

The study authors would like to express their gratitude to AstraZeneca for their unrestricted funding of this project.




Figure (1): Model Structure of Budget Impact Analysis